search
Back to results

The Impact of Low Pressure Pneumo in RARP II

Primary Purpose

Prostate Cancer

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pressure applied during RARP
Sponsored by
Metro Health, Michigan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Prostate Cancer focused on measuring Radical Prostatectomy, Robotic Assisted Radical Prostatectomy

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

- Male 40 years of age or older

  • Diagnosis of prostate cancer
  • Have been evaluated to be fit for proposed surgery
  • Patients able to consent

Exclusion Criteria:

- Patients unable to consent (cognitively impaired)

• Non-English speaking

Sites / Locations

  • Metro Health-University of Michigan HealthRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Reduction in Pressure

Standard Amount of Pressure

Arm Description

This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.

This group receives 15mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.

Outcomes

Primary Outcome Measures

Reduction of Post-Operative Ileus
Reduction in the occurrence of Post-Operative Ileus after RARP

Secondary Outcome Measures

Reduction in narcotic use
Reduction in the need for narcotics post operatively
Reduction in Estimated Blood Loss during RARP
Reduced blood loss during robot assisted radical prostatectomy
Reduction in post operative complications as measured by Clavien-Dindo Complication Score
Reduction in post operative complications as measured by Clavien-Dindo Complication Score

Full Information

First Posted
May 14, 2020
Last Updated
October 11, 2023
Sponsor
Metro Health, Michigan
search

1. Study Identification

Unique Protocol Identification Number
NCT04394676
Brief Title
The Impact of Low Pressure Pneumo in RARP II
Official Title
The Impact of Low Pressure Pneumoperitoneum in Robotic Assisted Radical Prostatectomy: A Prospective Randomized Controlled Trial II
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 4, 2020 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Metro Health, Michigan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate clinical significance of low pressure pneumoperitoneum during robotically assisted radical prostatectomy (RARP).
Detailed Description
Laparoscopic and robotic surgery has revolutionized post-operative outcomes across surgical specialties. However, the use of pneumoperitoneum comes with known risks given the change in physiological parameters that accompany its utilization. The effects of increased intra-abdominal pressure on cardiopulmonary function has been well documented. Increased pressure on the large vessels may lead to decreased cardiac output and thereby decreased blood flow to various organ systems and cause irreversible damage. Some studies have advocated lower pressures to further optimize cardiopulmonary parameters. McDougall, et. al, for instance, demonstrated a significant reduction in oliguria when pressures of 10mm Hg were used. The purpose of this study is to evaluate the effect of using lower pressure pneumoperitoneum in the abdominal cavity during RARP. The investigators hypothesize that low pressure pneumoperitoneum has a multitude of clinical benefits due to improved physiologic parameters including a reduction in the occurrence of post-operative ileus, reduced need for narcotics post operatively, and a decrease in cardiopulmonary complications. A previously completed study concluded a reduction in post-operative ileus at a pneumoperitoneum pressure of 8 mm Hg vs 12 mm Hg. This new study will evaluate the standard pneumoperitoneum pressure of 15 mm Hg vs 12 mm Hg in order to validate the previous study vs the standard pneumoperitoneum pressure. The study is a prospective randomized blinded cohort study. Patients who meet eligibility criteria will be randomly assigned to undergo RARP at a pneumoperitoneum pressure of 15mm Hg or 12mm Hg. This will be done by computer generated randomization protocol. Surgeon and patients will be blinded to the pneumoperitoneum pressure used. A cover will be placed over the insufflation system so that the surgeon(s) are not able to visualize the pneumoperitoneum used during the procedure. The remainder of the procedure will be carried out based on current standard of care. All patients will be admitted post operatively and the same standardized orderset in EPIC EHR will be used for all patients in order to control for other factors, such as opioid use, to control for confounders.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
Radical Prostatectomy, Robotic Assisted Radical Prostatectomy

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, Randomized Trial
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Reduction in Pressure
Arm Type
Experimental
Arm Description
This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
Arm Title
Standard Amount of Pressure
Arm Type
Active Comparator
Arm Description
This group receives 15mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
Intervention Type
Procedure
Intervention Name(s)
Pressure applied during RARP
Intervention Description
Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).
Primary Outcome Measure Information:
Title
Reduction of Post-Operative Ileus
Description
Reduction in the occurrence of Post-Operative Ileus after RARP
Time Frame
An average of 3 days
Secondary Outcome Measure Information:
Title
Reduction in narcotic use
Description
Reduction in the need for narcotics post operatively
Time Frame
An average of 3 days
Title
Reduction in Estimated Blood Loss during RARP
Description
Reduced blood loss during robot assisted radical prostatectomy
Time Frame
An average of 1 hour
Title
Reduction in post operative complications as measured by Clavien-Dindo Complication Score
Description
Reduction in post operative complications as measured by Clavien-Dindo Complication Score
Time Frame
Up to 30 days after procedure

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Male 40 years of age or older Diagnosis of prostate cancer Have been evaluated to be fit for proposed surgery Patients able to consent Exclusion Criteria: - Patients unable to consent (cognitively impaired) • Non-English speaking
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kevin Keating, DO
Phone
616-252-5026
Email
kevin.keating@umhwest.org
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Maatman, DO
Phone
616-252-5026
Email
maatmant@aol.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Maatman, DO
Organizational Affiliation
Michigan Urological Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Metro Health-University of Michigan Health
City
Wyoming
State/Province
Michigan
ZIP/Postal Code
49519
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cindy Karl, BSN
Phone
616-252-4971
Email
cindy.karl@metrogr.org
First Name & Middle Initial & Last Name & Degree
Joan Westendorp, BSN
Phone
616-252-4973
Email
joan.westendorp@umhwest.org
First Name & Middle Initial & Last Name & Degree
Kevin Keating, DO

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Impact of Low Pressure Pneumo in RARP II

We'll reach out to this number within 24 hrs